This biomarker is also known as:
- oncogene RHO H12,
- small GTP binding protein RhoA,
- transforming protein RhoA,
- Aplysia ras-related homolog 12,
- ras homolog gene family, member A,
- rho cDNA clone 12,
- Rho cDNA clone 12,
- ras homolog family member A,
View in BioMuta
RHOA is a member of the small GTPase superfamily. RHO family GTPases are involved in many basic cellular processes that influence cell proliferation, differentiation, motility, adhesion, survival, or secretion. RHOA regulates a signal transduction pathway linking plasma membrane receptors to the assembly of focal adhesions and actin stress fibers.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
RHOA has been shown to be involved in hypoxia-inducible factor-mediated RHOA expression and signaling in breast cancer cells.
RHOA was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
This biomarker is currently being annotated or is under review.
You must be logged in
or do not have permission to view any additional information. Contact Heather Kincaid at
if you should have access to this biomarker.
Update: Pre-application webinar information now available.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.